Anti-HER2 cancer therapy and cardiotoxicity.
Anti-HER2 cancer therapy and cardiotoxicity.
复制标题
DOI：
10.2174/1381612820666140604145037
复制
发表时间：
2014-08
影响因子：
3.1
通讯作者：
T. Babar;Christopher P. Blomberg;Eileen Hoffner;Xinhua Yan
中科院分区：
文献类型：
--
作者：
T. Babar;Christopher P. Blomberg;Eileen Hoffner;Xinhua Yan
乳腺癌治疗的一个重要里程碑是确定 HER2 受体作为癌症治疗的药物靶点。曲妥珠单抗（赫赛汀）是一种阻断 HER2 受体的单克隆抗体，是美国食品和药物管理局首批批准用于靶向癌症治疗的此类药物之一。临床研究表明，曲妥珠单抗可显着提高乳腺癌患者的总体生存率。然而，心脏毒性的不可预见的显着副作用表现为左心室功能障碍和心力衰竭。同时进行的研究证明了 HER2 受体在心脏发育和维持成人心脏生理功能中的重要作用。因此，HER2 受体已成为肿瘤学和心脏病学领域之间的关键纽带。除曲妥珠单抗外，针对 HER2 受体的新药，如拉帕替尼、帕妥珠单抗和阿法替尼，已获批准或正在临床试验中评估用于癌症治疗。由于担心 HER2 抑制引起的心脏毒性，很明显需要开发新的治疗策略来预防此类心脏副作用。本文的目的是回顾抗 HER2 癌症治疗对心脏的潜在影响。
A significant milestone in the treatment of breast cancer is the identification of the HER2 receptor as a drug target for cancer therapies. Trastuzumab (Herceptin), a monoclonal antibody that blocks the HER2 receptor, is among the first of such drugs approved by the US Food and Drug Administration for targeted cancer therapy. Clinical studies have shown that Trastuzumab significantly improves the overall survival of breast cancer patients. However, an unforeseen significant side-effect of cardiotoxicity manifested as left ventricular dysfunction and heart failure. Concurrent studies have demonstrated the essential role of the HER2 receptor in cardiac development and maintaining the physiological function of an adult heart. The HER2 receptor, therefore, has become a critical link between the oncology and cardiology fields. In addition to Trastuzumab, new drugs targeting the HER2 receptor, such as Lapatinib, Pertuzumab and Afatinib, are either approved or being evaluated in clinical trials for cancer therapy. With the concern of cardiotoxicity caused by HER2 inhibition, it becomes clear that new therapeutic strategies for preventing such cardiac side effects need to be developed. It is the intent of this paper to review the potential cardiac impact of anti-HER2 cancer therapy.